Valiant Laboratories Limited (NSE:VALIANTLAB)
India · Delayed Price · Currency is INR 91.99
+1.14 (1.25%)
Aug 19, 2026, 3:29 PM IST
Valiant Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 3,059 | 2,375 | 1,334 | 1,821 | 3,339 | 3,124 | |
Revenue Growth | 89.64% | 78.04% | -26.74% | -45.48% | 6.90% | - |
Cost of Revenue | 2,252 | 1,972 | 1,170 | 1,705 | 2,789 | 2,530 |
Gross Profit | 807.29 | 403.04 | 163.9 | 115.76 | 549.82 | 594.07 |
Selling, General & Admin | 84.02 | 69.98 | 43.88 | 43.13 | 46.13 | 33.44 |
Other Operating Expenses | 390.78 | 269.16 | 166.81 | 156.71 | 152.79 | 101.43 |
Operating Expenses | 558.48 | 399.54 | 231.62 | 219.49 | 214.55 | 159.13 |
Operating Income | 248.8 | 3.5 | -67.72 | -103.73 | 335.28 | 434.94 |
Interest Expense | -28.96 | -19.03 | -1.74 | -0.78 | -2.54 | -0.36 |
Interest & Investment Income | - | - | 30.27 | 26.77 | 0.97 | 8.31 |
Currency Exchange Gain (Loss) | - | - | -0.15 | 2.89 | 5.83 | 8.72 |
Other Non Operating Income (Expenses) | 25.25 | 23.21 | 19.48 | 58.74 | 3.45 | 1.05 |
EBT Excluding Unusual Items | 245.1 | 7.68 | -19.86 | -16.11 | 342.99 | 452.66 |
Gain (Loss) on Sale of Investments | - | - | 4.73 | 8.42 | 38.37 | - |
Pretax Income | 245.1 | 7.68 | -15.13 | -7.7 | 381.36 | 452.66 |
Income Tax Expense | 84.96 | 40.36 | 6.89 | -10.89 | 91.38 | 111.93 |
Net Income | 160.14 | -32.68 | -22.01 | 3.2 | 289.98 | 340.74 |
Net Income to Common | 160.14 | -32.68 | -22.01 | 3.2 | 289.98 | 340.74 |
Net Income Growth | 12314.11% | - | - | -98.90% | -14.89% | - |
Shares Outstanding (Basic) | 67 | 64 | 43 | 38 | 33 | 33 |
Shares Outstanding (Diluted) | 67 | 64 | 43 | 38 | 33 | 33 |
Shares Change | 53.96% | 47.47% | 14.33% | 16.72% | - | - |
EPS (Basic) | 2.40 | -0.51 | -0.51 | 0.08 | 8.91 | 10.46 |
EPS (Diluted) | 2.40 | -0.51 | -0.51 | 0.08 | 8.91 | 10.46 |
EPS Growth | 7963.68% | - | - | -99.06% | -14.88% | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -446.32 | -1,125 | -439.85 | 183.7 | 49.48 |
Free Cash Flow Per Share | - | -6.96 | -25.90 | -11.57 | 5.64 | 1.52 |
Gross Margin | 26.39% | 16.97% | 12.29% | 6.36% | 16.47% | 19.02% |
Operating Margin | 8.13% | 0.15% | -5.08% | -5.70% | 10.04% | 13.92% |
Profit Margin | 5.24% | -1.38% | -1.65% | 0.18% | 8.68% | 10.91% |
Free Cash Flow Margin | - | -18.80% | -84.37% | -24.16% | 5.50% | 1.58% |
EBITDA | 319.55 | 63.9 | -48.7 | -85.98 | 349.23 | 456.55 |
EBITDA Margin | 10.45% | 2.69% | -3.65% | -4.72% | 10.46% | 14.62% |
D&A For EBITDA | 70.74 | 60.4 | 19.02 | 17.75 | 13.95 | 21.61 |
EBIT | 248.8 | 3.5 | -67.72 | -103.73 | 335.28 | 434.94 |
EBIT Margin | 8.13% | 0.15% | -5.08% | -5.70% | 10.04% | 13.92% |
Effective Tax Rate | 34.66% | 525.40% | - | - | 23.96% | 24.73% |
Revenue as Reported | 3,085 | 2,398 | 1,388 | 1,917 | 3,388 | 3,149 |